Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen's Harper Says Repatha Is Priced Right

Executive Summary

The things that keep Sean Harper up at night have changed over the last few years as science has advanced and the drug development landscape has changed. Harper, who is the head of R&D at big biotech Amgen Inc., once worried that his company wouldn't be able to keep up, now he's concerned with where the money is going to come from.

Advertisement

Related Content

Regeneron: PCSK9s Drowning In Paperwork
PCSK9s: Discount Prompts NICE Turnaround on Sanofi's Praluent
More Troubles For Martin Shkreli – That Guy Drug Makers Despise
Amgen Earnings Beat Expectations; Company Pushing Payers On Repatha
Regrets For Valeant's Ackman, Pearson; Big Pay For Papa
Industry's Rebate Arms Race: Securing Market Access At A Cost
Express Scripts Repatha, Praluent Deals: What It Means

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065113

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel